Skip to main content

Advertisement

Log in

Psychopharmacology in Cancer

  • Complex Medical-Psychiatric Issues (MB Riba, Section Editor)
  • Published:
Current Psychiatry Reports Aims and scope Submit manuscript

Abstract

Depression, anxiety, delirium, and other psychiatric symptoms are highly prevalent in the cancer setting, and pharmacological intervention is an important component in the overall psychosocial care of the patient. Psychopharmacology is also used as a primary or adjuvant treatment for the management of cancer-related symptoms stemming from the disease itself and/or its treatment, including sleep disturbance, loss of appetite, neuropathic pain, nausea, fatigue, and hot flashes. Psychiatrists, oncologists, and palliative care physicians working as members of a multidisciplinary team have the opportunity to target multiple symptoms that negatively affect a patient’s quality of life with the strategic use of psychotropic medications when deemed appropriate. This article aims to review the indications for use of antidepressants, psychostimulants, anxiolytics, antipsychotics, and mood stabilizers in oncology. An updated review of the relevant literature is discussed and referenced in each section.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Mitchell AJ et al. Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: a meta-analysis of 94 interview-based studies. Lancet Oncol. 2011;12(2):160–74.

    Article  PubMed  Google Scholar 

  2. Pirl WF, Roth AJ. Diagnosis and treatment of depression in cancer patients. Oncology (Williston Park). 1999;13(9):p. 1293–301. Discussion 1301–2, 1305–6.

    Google Scholar 

  3. Holland JC et al. Distress management. J Natl Compr Canc Netw. 2013;11(2):190–209.

    PubMed  Google Scholar 

  4. American Psychiatric Association (2013) Diagnostic and Statistical Manual of Mental Disorders DSM-5, 5th edn. American Psychiatric Association, Washington, DC

  5. Lee BN et al. A cytokine-based neuroimmunologic mechanism of cancer-related symptoms. Neuroimmunomodulation. 2004;11(5):279–92.

    Article  CAS  PubMed  Google Scholar 

  6. Thekdi SM IM, Dunn L. Psychopharmacological interventions. In: Grassi RM, editor. Clinical psych-oncology: an international perspective. Chichester: Wiley-Blackwell; 2012. p. 109–26.

    Chapter  Google Scholar 

  7. Desplenter F et al. Incidence and drug treatment of emotional distress after cancer diagnosis: a matched primary care case-control study. Br J Cancer. 2012;107(9):1644–51.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  8. Ng CG et al. Prescription patterns for psychotropic drugs in cancer patients; a large population study in the Netherlands. Psychooncology. 2013;22(4):762–7.

    Article  PubMed  Google Scholar 

  9. Caruso R et al. Psychopharmacology in psycho-oncology. Curr Psychiatry Rep. 2013;15(9):393.

    Article  PubMed  Google Scholar 

  10. Grassi L et al. Efficacy and safety of pharmacotherapy in cancer-related psychiatric disorders across the trajectory of cancer care: a review. Int Rev Psychiatry. 2014;26(1):44–62. This review article includes a search of the major databases (MEDLINE, Embase, PsycLIT, PsycINFO, the Cochrane Library) and summarizes relevant data concerning the efficacy and safety of pharmacotherapy for cancer-related psychiatric disorders in cancer patients across the trajectory of the disease.

    Article  PubMed  Google Scholar 

  11. McDaniel JS et al. Depression in patients with cancer. Diagnosis, biology, and treatment. Arch Gen Psychiatry. 1995;52:89–99.

    Article  CAS  PubMed  Google Scholar 

  12. Sharpe M et al. Major depression in outpatients attending a regional cancer centre: screening and unmet treatment needs. Br J Cancer. 2004;90(2):314–20.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  13. Strouse TB. Psychopharmacologic treatment of depression in patients with cancer: a 2013 update. FOCUS 2013. 2013;11:450–9.

    Google Scholar 

  14. Stockler MR, O’Connell R, Nowak AK, et al. Effects of sertraline on symptoms and survival in patients with advanced cancer, but without major depression: a placebo-controlled double-blind randomised trial. Lancet Oncol. 2007;8:603–12.

    Article  CAS  PubMed  Google Scholar 

  15. Miller AH. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry. 2008;65(9):p. 732–741.

    Article  Google Scholar 

  16. Danzer R, O’Connor J, Freund GG. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci. 2008;9:46–56.

    Article  Google Scholar 

  17. Tynan RJ et al. A comparative examination of the anti-inflammatory effects of SSRI and SNRI antidepressants on LPS stimulated microglia. Brain Behav Immun. 2012;26(3):469–79.

    Article  CAS  PubMed  Google Scholar 

  18. Mun AR et al. Fluoxetine-induced apoptosis in hepatocellular carcinoma cells. Anticancer Res. 2013;33(9):3691–7.

    CAS  PubMed  Google Scholar 

  19. De Fazio P et al. Mental adjustment to cancer: the role of anxious and depressive symptoms under treatment. Int J Psychiatry Med. 2013;46(4):375–86.

    Article  PubMed  Google Scholar 

  20. Strong V et al. Management of depression for people with cancer 4 (SMaRT oncology 1): a randomised trial. Lancet. 2008;372(9632):40–8.

    Article  PubMed  Google Scholar 

  21. Holland JC et al. A controlled trial of fluoxetine and desipramine in depressed women with advanced cancer. Psychooncology. 1998;7(4):291–300.

    Article  CAS  PubMed  Google Scholar 

  22. Fisch MJ et al. Fluoxetine versus placebo in advanced cancer outpatients: a double-blinded trial of the Hoosier Oncology Group. J Clin Oncol. 2003;21(10):1937–43.

    Article  CAS  PubMed  Google Scholar 

  23. Schillani G et al. Pharmacogenetics of escitalopram and mental adaptation to cancer in palliative care: report of 18 cases. Tumori. 2011;97(3):358–61.

    PubMed  Google Scholar 

  24. Lydiatt WM et al. Prevention of depression with escitalopram in patients undergoing treatment for head and neck cancer randomized, double-blind, placebo-controlled clinical trial. JAMA Otolaryngol-Head Neck Surg. 2013;139(7):p. 678–686. This is an interesting study suggesting that certain depressive states can be prevented, in turn abutting the issue of whether certain depressive states in cancer may be explained by biochemically identifiable mechanisms such as inflammation.

    Google Scholar 

  25. Callari A et al. Treatment of depression in patients with breast cancer: a critical review. Tumori. 2013;99(5):p. 623–633. This article reviews the relevant evidence for the efficacy of SSRIs in breast cancer. The importance of the study is that it separates certain forms of pharmacologically treatable depression from general distress in cancer patients.

    Google Scholar 

  26. Kim SW et al. Effectiveness of mirtazapine for nausea and insomnia in cancer patients with depression. Psychiatry Clin Neurosci. 2008;62(1):75–83.

    Article  CAS  PubMed  Google Scholar 

  27. Moss EL et al. An open-label study of the effects of bupropion SR on fatigue, depression and quality of life of mixed-site cancer patients and their partners. Psychooncology. 2006;15(3):259–67.

    Article  PubMed  Google Scholar 

  28. Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. Cochrane Database Syst Rev. 2007;4, CD005454.

    PubMed  Google Scholar 

  29. Smith EM et al. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA. 2013;309(13):1359–67.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  30. Amr YM, Yousef AA. Evaluation of efficacy of the perioperative administration of venlafaxine or gabapentin on acute and chronic postmastectomy pain. Clin J Pain. 2010;26(5):381–5.

    Article  PubMed  Google Scholar 

  31. Durand JP et al. Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial. Ann Oncol. 2012;23(1):200–5.

    Article  CAS  PubMed  Google Scholar 

  32. L’Esperance S et al. Pharmacological and non-hormonal treatment of hot flashes in breast cancer survivors: CEPO review and recommendations. Support Care Cancer. 2013;21(5):1461–74.

    Article  PubMed  Google Scholar 

  33. Miguel C, Albuquerque E. Drug interaction in psycho-oncology: antidepressants and antineoplastics. Pharmacology. 2011;88(5–6):333–9.

    Article  CAS  PubMed  Google Scholar 

  34. Desmarais JE, Looper KJ. Interactions between tamoxifen and antidepressants via cytochrome P450 2D6. J Clin Psychiatry. 2009;70(12):1688–97.

    Article  CAS  PubMed  Google Scholar 

  35. Kelly CM et al. Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. Br Med J. 2010;340.

  36. Regan MM et al. CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial. J Natl Cancer Inst. 2012;104(6):441–51.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  37. Rae JM et al. CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J Natl Cancer Inst. 2012;104(6):452–60.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  38. Zembutsu H et al. Should CYP2D6 inhibitors be administered in conjunction with tamoxifen? Expert Rev Anticancer Ther. 2011;11(2):185–93.

    Article  CAS  PubMed  Google Scholar 

  39. Ahmad A, Shahabuddin S, Sheikh S. Endoxifen, a new cornerstone of breast cancer therapy: demonstration of safety, tolerability, and systemic bioavailability in healthy human subjects. Clin Pharmacol Ther. 2010;88(6):814–7.

    Article  CAS  PubMed  Google Scholar 

  40. Portenoy RK et al. The memorial symptom assessment scale: an instrument for the evaluation of symptom prevalence, characteristics and distress. Eur J Cancer. 1994;30A(9):1326–36.

    Article  CAS  PubMed  Google Scholar 

  41. Macleod AD. Methylphenidate in terminal depression. J Pain Symptom Manag. 1998;16(3):193–8.

    Article  CAS  Google Scholar 

  42. Olin J, Masand P. Psychostimulants for depression in hospitalized cancer patients. Psychosomatics. 1996;37(1):57–62.

    Article  CAS  PubMed  Google Scholar 

  43. Bruera E et al. The use of methylphenidate in patients with incident cancer pain receiving regular opiates. A preliminary report. Pain. 1992;50(1):75–7.

    Article  CAS  PubMed  Google Scholar 

  44. Gagnon B, Low G, Schreier G. Methylphenidate hydrochloride improves cognitive function in patients with advanced cancer and hypoactive delirium: a prospective clinical study. J Psychiatry Neurosci. 2005;30(2):100–7.

    PubMed Central  PubMed  Google Scholar 

  45. Prommer E. Methylphenidate: established and expanding roles in symptom management. Am J Hosp Palliat Care. 2012;29(6):483–90.

    Article  PubMed  Google Scholar 

  46. Minton O et al. Drug therapy for the management of cancer-related fatigue. Cochrane Database Syst Rev. 2010;7, CD006704.

    PubMed  Google Scholar 

  47. Roth AJ et al. Methylphenidate for fatigue in ambulatory men with prostate cancer. Cancer. 2010;116(21):5102–10.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  48. Bruera E et al. Methylphenidate and/or a nursing telephone intervention for fatigue in patients with advanced cancer: a randomized, placebo-controlled, phase II trial. J Clin Oncol. 2013;31(19):2421–7.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  49. Moraska AR et al. Phase III, randomized, double-blind, placebo-controlled study of long-acting methylphenidate for cancer-related fatigue: North Central Cancer Treatment Group NCCTG-N05C7 trial. J Clin Oncol. 2010;28(23):3673–9.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  50. Jean-Pierre P et al. A phase 3 randomized, placebo-controlled, double-blind, clinical trial of the effect of modafinil on cancer-related fatigue among 631 patients receiving chemotherapy: a University of Rochester Cancer Center Community Clinical Oncology Program Research base study. Cancer. 2010;116(14):3513–20.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  51. Spathis A et al. Modafinil for the treatment of fatigue in lung cancer: results of a placebo-controlled, double-blind, randomized trial. J Clin Oncol. 2014;32(18):1882–8.

    Article  CAS  PubMed  Google Scholar 

  52. Breitbart W, Alici Y. Evidence-based treatment of delirium in patients with cancer. J Clin Oncol. 2012;30(11):1206–14.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  53. Yoon HJ et al. Efficacy and safety of haloperidol versus atypical antipsychotic medications in the treatment of delirium. BMC Psychiatry. 2013;13:240.

    Article  PubMed Central  PubMed  Google Scholar 

  54. Boettger S, Breitbart W. An open trial of aripiprazole for the treatment of delirium in hospitalized cancer patients. Palliat Support Care. 2011;9(4):351–7.

    Article  PubMed  Google Scholar 

  55. Maldonado JR. Delirium in the acute care setting: characteristics, diagnosis and treatment. Crit Care Clin. 2008;24(4):657–722. vii.

    Article  CAS  PubMed  Google Scholar 

  56. Wang HR, Woo YS, Bahk WM. Atypical antipsychotics in the treatment of delirium. Psychiatry Clin Neurosci. 2013;67(5):p. 323–31. This paper reviews six prospective, randomized controlled studies evaluating the efficacy, safety, and tolerability of atypical antipsychotics in the treatment of delirium.

    Article  Google Scholar 

  57. Yoon HK et al. Paliperidone in the treatment of delirium: results of a prospective open-label pilot trial. Acta Neuropsychiatrica. 2011;23(4):179–83.

    Article  PubMed  Google Scholar 

  58. Anderson R et al. Lurasidone for the management of intensive care unit (ICU)-associated delirium. Crit Care Med. 2012;40(12):1–328.

  59. Teslyar P et al. Prophylaxis with antipsychotic medication reduces the risk of post-operative delirium in elderly patients: a meta-analysis. Psychosomatics. 2013;54(2):p. 124–31. This paper reviews five studies examining the use of antipsychotics (haloperidol, risperidone, and olanzapine) in the prevention of postoperative delirium in elderly patients. Pooled analysis revealed a relative risk reduction of 50 % versus placebo.

    Article  Google Scholar 

  60. Pasquini M, Speca A, Biondi M. Quetiapine for tamoxifen-induced insomnia in women with breast cancer. Psychosomatics. 2009;50(2):159–61.

    Article  CAS  PubMed  Google Scholar 

  61. Prommer E. Olanzapine: palliative medicine update. Am J Hosp Palliat Care. 2013;30(1):75–82.

    Article  PubMed  Google Scholar 

  62. Han C et al. Second-generation antipsychotics in the treatment of major depressive disorder: current evidence. Expert Rev Neurother. 2013;13(7):851–70.

    Article  CAS  PubMed  Google Scholar 

  63. Lorenz RA, Jackson CW, Saitz M. Adjunctive use of atypical antipsychotics for treatment-resistant generalized anxiety disorder. Pharmacotherapy. 2010;30(9):942–51.

    Article  CAS  PubMed  Google Scholar 

  64. McLean SL, Blenkinsopp A, Bennett MI. Using haloperidol as an antiemetic in palliative care: informing practice through evidence from cancer treatment and postoperative contexts. J Pain Palliat Care Pharmacother. 2013;27(2):132–5.

    Article  PubMed  Google Scholar 

  65. Smith HH. Palliative Medicine. Philadelphia: Saunders Elsevier; 2009. p. 894–8.

    Book  Google Scholar 

  66. Hocking CM, Kichenadasse G. Olanzapine for chemotherapy-induced nausea and vomiting: a systematic review. Support Care Cancer. 2014;22(4):1143–51.

    Article  PubMed  Google Scholar 

  67. Navari RM, Brenner MC. Treatment of cancer-related anorexia with olanzapine and megestrol acetate: a randomized trial. Support Care Cancer. 2010;18(8):951–6.

    Article  PubMed  Google Scholar 

  68. Rahman T et al. Antipsychotic treatment in breast cancer patients. Am J Psychiatry. 2014;171(6):p. 616–21. This paper reviews the issue of prescribing antipsychotics in the context of breast cancer, a concern often raised by patients to their clinicians requiring the most up-to-date information.

    Article  Google Scholar 

  69. Leucht S et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382(9896):951–62.

    Article  CAS  PubMed  Google Scholar 

  70. Linden W et al. Anxiety and depression after cancer diagnosis: prevalence rates by cancer type, gender, and age. J Affect Disord. 2012;141(2–3):343–51.

    Article  PubMed  Google Scholar 

  71. Noyes R, Holt C, Massie M. Anxiety disorders. In: Holland J, editor. Psycho-oncology. New York: Oxford University Press; 1998. p. 548–63.

    Google Scholar 

  72. Miller K, Massie MJ. Depression and anxiety. Cancer J. 2006;12(5):388–97.

    Article  CAS  PubMed  Google Scholar 

  73. Prieto JM et al. Psychiatric morbidity and impact on hospital length of stay among hematologic cancer patients receiving stem-cell transplantation. J Clin Oncol. 2002;20(7):1907–17.

    Article  PubMed  Google Scholar 

  74. Lavigne JE et al. A randomized, controlled, double-blinded clinical trial of gabapentin 300 versus 900 mg versus placebo for anxiety symptoms in breast cancer survivors. Breast Cancer Res Treat. 2012;136(2):479–86.

    Article  CAS  PubMed  Google Scholar 

  75. Lindgren ME et al. Beta-blockers may reduce intrusive thoughts in newly diagnosed cancer patients. Psychooncology. 2013;22(8):p. 1889–94. The results of this study suggest that beta-blocker use may benefit cancer patients’ psychological adjustment following diagnosis, and provide a promising direction for future investigations on the pharmacological benefits of beta-blockers for cancer-related distress.

    Article  Google Scholar 

  76. Dundar Y et al. Comparative efficacy of newer hypnotic drugs for the short-term management of insomnia: a systematic review and meta-analysis. Hum Psychopharmacol. 2004;19(5):305–22.

    Article  PubMed  Google Scholar 

  77. Terzano MG et al. New drugs for insomnia: comparative tolerability of zopiclone, zolpidem and zaleplon. Drug Saf. 2003;26(4):261–82.

    Article  CAS  PubMed  Google Scholar 

  78. Moore TA, Berger AM, Dizona P. Sleep aid use during and following breast cancer adjuvant chemotherapy. Psychooncology. 2011;20(3):321–5.

    Article  PubMed Central  PubMed  Google Scholar 

  79. Costantini C, Ale-Ali A, Helsten T. Sleep aid prescribing practices during neoadjuvant or adjuvant chemotherapy for breast cancer. J Palliat Med. 2011;14(5):563–6.

    Article  PubMed  Google Scholar 

  80. Joffe H et al. Augmentation of venlafaxine and selective serotonin reuptake inhibitors with zolpidem improves sleep and quality of life in breast cancer patients with hot flashes: a randomized, double-blind, placebo-controlled trial. Menopause. 2010;17(5):908–16.

    Article  PubMed  Google Scholar 

  81. Candy B et al. Drug therapy for symptoms associated with anxiety in adult palliative care patients. Cochrane Database Syst Rev. 2012;10:Cd004596.

    PubMed  Google Scholar 

  82. Testa A et al. Psychiatric emergencies (part II): psychiatric disorders coexisting with organic diseases. Eur Rev Med Pharmacol Sci. 2013;17 Suppl 1:65–85.

    PubMed  Google Scholar 

  83. Vaidya R et al. Benzodiazepine use in breast cancer survivors: findings from a consecutive series of 1,000 patients. Oncology. 2011;81(1):p. 9–11. This study reports the percentage of breast cancer survivors (almost 8 %) receiving ongoing benzodiazepines and the circumstances surrounding their usage following 1000 consecutive women with breast cancers.

    Article  Google Scholar 

  84. Altamura AC et al. Mood stabilizers for patients with bipolar disorder: the state of the art. Expert Rev Neurother. 2011;11(1):85–99.

    Article  PubMed  Google Scholar 

  85. Kargiotis O, Markoula S, Kyritsis AP. Epilepsy in the cancer patient. Cancer Chemother Pharmacol. 2011;67(3):489–501.

    Article  CAS  PubMed  Google Scholar 

  86. Eisenberg E et al. Antiepileptic drugs in the treatment of neuropathic pain. Drugs. 2007;67(9):1265–89.

    Article  CAS  PubMed  Google Scholar 

  87. Petrini M, Azzara A. Lithium in the treatment of neutropenia. Curr Opin Hematol. 2012;19(1):52–7.

    Article  CAS  PubMed  Google Scholar 

  88. Khasraw M et al. Using lithium as a neuroprotective agent in patients with cancer. BMC Med. 2012;10:131.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  89. Bowden CL. Spectrum of effectiveness of valproate in neuropsychiatry. Expert Rev Neurother. 2007;7(1):9–16.

    Article  CAS  PubMed  Google Scholar 

  90. Andersohn F et al. Use of antiepileptic drugs in epilepsy and the risk of self-harm or suicidal behavior. Neurology. 2010;75(4):335–40.

    Article  CAS  PubMed  Google Scholar 

  91. Guthrie GD, Eljamel S. Impact of particular antiepileptic drugs on the survival of patients with glioblastoma multiforme. J Neurosurg. 2013;118(4):859–65.

    Article  CAS  PubMed  Google Scholar 

  92. Yap KY, Chui WK, Chan A. Drug interactions between chemotherapeutic regimens and antiepileptics. Clin Ther. 2008;30(8):1385–407.

    Article  CAS  PubMed  Google Scholar 

  93. Loprinzi CL, Barton DL, Qin R. Nonestrogenic management of hot flashes. J Clin Oncol. 2011;29(29):3842–6.

    Article  PubMed  Google Scholar 

  94. Loprinzi CL et al. Phase III, randomized, double-blind, placebo-controlled evaluation of pregabalin for alleviating hot flashes, N07C1. J Clin Oncol. 2010;28(4):641–7.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  95. Bar Ad V. Gabapentin for the treatment of cancer-related pain syndromes. Rev Recent Clin Trials. 2010;5(3):174–8.

    Article  PubMed  Google Scholar 

  96. Bennett MI et al. Pregabalin for the management of neuropathic pain in adults with cancer: a systematic review of the literature. Pain Med. 2013;14(11):1681–8.

    Article  PubMed  Google Scholar 

  97. Anand S. Gabapentin for pruritus in palliative care. Am J Hosp Palliat Care. 2013;30(2):192–6.

    Article  PubMed  Google Scholar 

  98. Ryan NM, Birring SS, Gibson PG. Gabapentin for refractory chronic cough: a randomised, double-blind, placebo-controlled trial. Lancet. 2012;380(9853):1583–9.

    Article  CAS  PubMed  Google Scholar 

  99. Wensel TM, Powe KW, Cates ME. Pregabalin for the treatment of generalized anxiety disorder. Ann Pharmacother. 2012;46(3):424–9.

    Article  PubMed  Google Scholar 

  100. Wiffen PJ, Derry S, Moore RA. Lamotrigine for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev. 2013;12, CD006044.

    PubMed  Google Scholar 

  101. Bendaly EA et al. Topiramate in the treatment of neuropathic pain in patients with cancer. Support Cancer Ther. 2007;4(4):241–6.

    Article  CAS  PubMed  Google Scholar 

  102. Reas DL, Grilo CM. Current and emerging drug treatments for binge eating disorder. Expert Opin Emerg Drugs. 2014;19:99–142.

    Article  CAS  PubMed  Google Scholar 

  103. Argyriou AA et al. Efficacy of oxcarbazepine for prophylaxis against cumulative oxaliplatin-induced neuropathy. Neurology. 2006;67(12):2253–5.

    Article  CAS  PubMed  Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Seema M. Thekdi, Antolin Trinidad, and Andrew Roth declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Seema M. Thekdi.

Additional information

This article is part of the Topical Collection on Complex-Medical Psychiatric Issues

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Thekdi, S.M., Trinidad, A. & Roth, A. Psychopharmacology in Cancer. Curr Psychiatry Rep 17, 529 (2015). https://doi.org/10.1007/s11920-014-0529-x

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11920-014-0529-x

Keywords

Navigation